Michael Quigley is the founder of Therini Bio. Therini Bio has raised $62M in total funding. Latest round: Series A. Based in Sacramento, CA.
Michael Quigley is the President and CEO of Therini Bio, a South San Francisco-based biotech company focused on developing fibrin-targeted therapies for inflammatory neurodegenerative and retinal diseases. Under his leadership, Therini Bio raised a $36 million Series A financing round, bringing their total funding to $62 million. The company aims to advance its lead antibody, THN391, into clinical trials to target inflammatory fibrin.
Full founder directory · Investor directory · Company funding database · Fundraising library